Gamma interferon loaded onto albumin nanoparticles: In vitro and in vivo activities against Brucella abortus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1310-1314

  Segura, S ^a   Gamazo, C ^b   Irache, J M ^a   Espuelas, S ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BRUCELLA ABORTUS; BRUCELLOSIS; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH2 CELL;

ALBUMINS; ANIMALS; BRUCELLA ABORTUS; BRUCELLOSIS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; INTERFERON TYPE II; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOSTRUCTURES;

EID: 34247119111     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00890-06     Document Type: Article

References (33)

1. Abe, Y., H. Shibata, H. Kamada, S. Tsunoda, Y. Tsutsumi, and S. Nakagawa. 2006. Promotion of optimized protein therapy by bioconjugation as a polymeric DDS. Anticancer Agents Med. Chem. 6:251-258.
2. Ahsan, F., I. P. Rivas, M. A. Khan, and A. I. Torres Suarez. 2002. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 79:29-40.
3. Badaro, R., and W. D. Johnson, Jr. 1993. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167(Suppl. 1):S13-S17.
4. Baldwin, C. L., and M. Parent. 2002. Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection. Vet. Microbiol. 90:367-382.
5. Degling, L., P. Stjarnkvist, and I. Sjoholm. 1993. Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice. Pharm. Res. 10:783-790.
6. Fernandes, D. M., and C. L. Baldwin. 1995. Interleukin-10 downregulates protective immunity to Brucella abortus. Infect. Immun. 63:1130-1133.
7. Forton, D., and P. Karayiannis. 2006. Established and emerging therapies for the treatment of viral hepatitis. Dig. Dis. 24:160-173.
8. Gross, A., S. Spiesser, A. Terraza, B. Rouot, E. Caron, and J. Demand. 1998. Expression and bactericidal activity of nitric oxide synthase in Brucella suis-infected murine macrophages. Infect. Immun. 66:1309-1316.
9. Gross, A., A. Terraza, S. Ouahrani-Bettache, J. P. Liautard, and J. Dornand. 2000. In vitro Brucella suis infection prevents the programmed cell death of human monocytic cells. Infect. Immun. 68:342-351.
10. Hamada, I., M. Kato, and K. Okada. 2002. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose. Anticancer Res. 22:2429-2436.
11. Huang, L. Y., C. Reis e Sousa, Y. Itoh, J. Inman, and D. E. Scott. 2001. IL-12 induction by a TH1-inducing adjuvant in vivo: dendritic cell subsets and regulation by IL-10. J. Immunol. 167:1423-1430.
12. Jiang, X., and C. L. Baldwin. 1993. Effects of cytokines on intracellular growth of Brucella abortus. Infect. Immun. 61:124-134.
13. Jiang, X., B. Leonard, R. Benson, and C. L. Baldwin. 1993. Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell. Immunol. 151:309-319.
14. Kedzierska, K., G. Paukovics, A. Handley, M. Hewish, J. Hocking, P. U. Cameron, and S. M. Crowe. 2004. Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals. HIV Clin. Trials 5:80-85.
15. Labro, M. T. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin. Microbiol. Rev. 13:615-650.
16. Lecaroz, C., M. J. Blanco-Prieto, M. A. Burrell, and C. Gamazo. 2006. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J. Antimicrob. Chemother. 58:549-556.
17. Lejeune, F. J., D. Lienard, M. Matter, and C. Ruegg. 2006. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6:6.
18. Marciano, B. E., R. Wesley, E. S. De Carlo, V. L. Anderson, L. A. Barnhart, D. Darnell, H. L. Malech, J. I. Gallin, and S. M. Holland. 2004. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin. Infect. Dis. 39:692-699.
19. Murphy, E. A., M. Parent, J. Sathiyaseelan, X. Jiang, and C. L. Baldwin. 2001. Immune control of Brucella abortus 2308 infections in BALB/c mice. FEMS Immunol. Med. Microbiol. 32:85-88.
20. Murphy, E. A., J. Sathiyaseelan, M. A. Parent, B. Zou, and C. L. Baldwin. 2001. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103:511-518.
21. Nathan, C. F., H. W. Murray, M. E. Wiebe, and B. Y. Rubin. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158:670-689.
22. + type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur. J. Immunol. 25:2551-2557.
23. Ouadrhiri, Y., and Y. Sibille. 2000. Phagocytosis and killing of intracellular pathogens: interaction between cytokines and antibiotics. Curr. Opin. Infect. Dis. 13:233-240.
24. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:375-386.
25. Prior, S., B. Gander, J. M. Irache, and C. Gamazo. 2005. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J. Antimicrob. Chemother. 55:1032-1036.
26. Segura, S., S. Espuelas, M. J. Renedo, and J. M. Irache. 2005. Potential of albumin nanoparticles as carriers for interferon gamma. Drug Dev. Ind. Pharm. 31:271-280.
27. Stevens, M. G., G. W. Pugh, Jr., and L. B. Tabatabai. 1992. Effects of gamma interferon and indomethacin in preventing Brucella abortus infections in mice. Infect. Immun. 60:4407-4409.
28. ten Hagen, T. L., W. van Vianen, and I. A. Bakker-Woudenberg. 1995. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J. Infect. Dis. 171:385-392.
29. van Slooten, M. L., O. Boerman, K. Romoren, E. Kedar, D. J. Crommelin, and G. Storm. 2001. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. Biochim. Biophys. Acta 1530:134-145.
30. van Slooten, M. L., I. Hayon, I. Babai, Z. Zakay-Rones, E. Wagner, G. Storm, and E. Kedar. 2001. Immunoadjuvant activity of interferon-gamma- liposomes co-administered with influenza vaccines. Biochim. Biophys. Acta 1531:99-110.
31. van Slooten, M. L., G. Storm, A. Zoephel, Z. Kupcu, O. Boerman, D. J. Crommelin, E. Wagner, and R. Kircheis. 2000. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm. Res. 17:42-48.
32. Younes, H. M., and B. G. Amsden. 2002. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J. Pharm. Sci. 91:2-17.
33. Zhan, Y., and C. Cheers. 1993. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect. Immun. 61:4899-4901.